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Drug and chemical induced photosensitivity from a clinical perspective 
Professor Sally Ibbotson 
Photobiology Unit, Dermatology Department, University of Dundee, Ninewells Hospital and 
Medical School, Dundee, DD1 9SY, UK 
 
Abstract 
Drug photosensitivity is a relatively common occurrence and a range of mechanisms may be 
involved. Some of these mechanisms will be discussed, including the most common, that of 
drug phototoxicity.  The potential for drug-induced photocarcinogenesis will also be covered. 
Different types of photosensitivity are addressed with respect to clinical presentation, 
mechanisms and additionally the contribution to our understanding through clinically directed 
investigations.  Repeated controlled therapeutic use of drug phototoxicity, with psoralen-UVA 
(PUVA) photochemotherapy and photodynamic therapy (PDT) will also be discussed. 
Introduction 
Abnormal cutaneous photosensitivity describes a pathological reaction of skin to light, generally 
ultraviolet radiation, manifest either as a heightened erythemal (sunburning) susceptibility or 
reaction or as a rash occurring after sun exposure.  There are a diverse range of causes of 
abnormal photosensitivity, which include those elicited by light alone (such as polymorphic light 
eruption or chronic actinic dermatitis) and those elicited by light activation of drug or chemical. 
Many commonly used drugs and chemicals absorb ultraviolet and/or visible radiation and 
therefore have the potential to cause photosensitisation.  These drugs and chemicals can be 
delivered exogenously through the systemic or topical route.  These include prescribed and 
“over the counter” medications and a variety of plants, dyes, non-steroidal anti-inflammatories 
and sunscreens that can cause abnormal topical photocontact reactions.  These drug and 
chemical photosensitivity reactions and the varied mechanisms involved, which are 
predominantly phototoxic and to a lesser extent photoallergic in nature, will be the focus of this 
review.  Accumulation of endogenous porphyrins within the spectrum of cutaneous porphyrias 
and the associated abnormal photosensitivity seen with these endogenous photosensitisers will 
not be included within this review.   
 
Thus, this highlights that there is immense diversity in the ways in which drug and chemical 
photosensitivity can present.  This is in part due to the route of delivery of the agent, but in 
addition, the characteristics of drug, chemical and patient and the mechanisms through which 
the abnormal photosensitisation is caused contribute to the heterogeneity of presentation and 
clinical features.  Much of what is discussed in relation to drug and chemical photosensitivity 
relates to occurrence as adverse events, which can be problematic clinically and with respect to 
the pharmaceutical industry and regulatory authorities.  However, the repeated controlled use 
of drug phototoxicity in the clinical setting must not be forgotten, as with the invaluable 
therapies employing psoralen-UVA photosensitisation (PUVA) (1) and with photodynamic 
therapy (PDT) (2). 
 
Whilst many drugs and chemicals absorb light in the ultraviolet and visible parts of the 
spectrum, interestingly, drug photosensitivity is not frequently documented, probably due in 
part to under-reporting, with affected subjects simply stopping drug if they develop an 
“exaggerated sunburn” or indeed attributing this to other causes, such as excessive sun 
exposure or a sunscreen reaction.  Indeed, if it occurs in patients who are otherwise unwell and 
receiving polypharmacy who may not be “out and about” it may not be clinically apparent and, 
as such, dermatologists and primary care physicians without a particular interest in 
photodermatology may only rarely see cases of drug-induced photosensitivity.   
 
Furthermore, it is very likely that idiosyncratic, probably genetic, factors come into play in 
determining susceptibility to drug-induced photosensitivity, at least in part and this is an 
evolving field of understanding.  In one report by Chaabane et al, of 118 patients presenting 
with a drug-induced skin adverse effect, photosensitivity was the third commonest cause (3).   
 
Within specialised photodiagnostic units, systemic drug-induced photosensitivity is generally 
reported to account for between 2-15% of photodermatoses diagnosed (4-8).  In our tertiary 
referral photodiagnostic unit, the Scottish Photobiology Service, systemic drug photosensitivity 
represented 4% of the cases diagnosed during the period from 1972 to 2017, consistent with 
other major photodiagnostic centres and photocontact allergic dermatitis represented an 
additional 2% of cases.  Interestingly, in one study of 229 patients with photosensitivity 
diseases, drug phototoxicity and phytophotodermatitis due to plant phototoxicity was 
documented more commonly in Caucasians (15.9% and 6.3% respectively) than in African-
Americans (0.7% and 0%), possibly indicating the protective effect of constitutive skin 
pigmentation against drug or chemical-induced phototoxicity (9).  In contrast, significant 
differences were not seen for some of the other photodermatoses, such as chronic actinic 
dermatitis and indeed photoallergic dermatitis, indicating that constitutive pigmentation does 
not protect against photosensitivity of all types, including those immunologically mediated (9).   
 
However, of course these cases only represent those actually referred for investigation of 
suspected photosensitivity and as such likely under-estimate the true occurrence in the 
population or in patient groups.  For example, in one report of patients with cystic fibrosis who 
received ciprofloxacin, almost half reported increased sun sensitivity in a questionnaire-based 
study when compared with only 2.4% of a control population (10). 
 
Action spectra 
There is a degree of predictability of photosensitivity based on spectroscopic and molecular 
characteristics, with a drug of low molecular weight and the presence of aromatic halogen 
atoms being more like to be associated with a photosensitivity (11).  Most photoactive drugs 
absorb light in the UVA region, sometimes extending into the visible part of the spectrum 
(mainly 315-430 nm), with the minority also sensitising in the UVB region (Figure 1).  This 
minority includes many commonly prescribed and over the counter medications, notably the 
thiazides, non-steroidal anti-inflammatories (NSAIDs) and quinine.  In one retrospective report 
of 14 patients diagnosed with drug-induced photosensitivity, monochromator phototesting 
showed UVA sensitivity in 10 subjects taking a range of drugs: quinine, sparfloxacin, 
amiodarone, doxycycline, mefenamic acid, nalidixic acid, fenbrufen, diclofenac, enalapril, 
diltiazem and prochlorperazine; one subject taking doxycycline was sensitive to UVA and UVB 
and three were tested off drug and had normal phototesting (12). 
 
Thus, given the UVA-dependency, drug-induced photosensitivity may manifest itself at any time 
of the year and also may be induced by UVA and visible light transmitted through window glass.  
Furthermore, broad-spectrum sunscreens may be of limited benefit with respect to protection 
against longer wavelength UVA and visible light photosensitisation.  The action spectra for 
induction of drug-induced photosensitivity must also be kept in mind with respect to patients 
receiving light-based therapies and may be problematic during UVB and UVA1 phototherapy, in 
terms of lowering of minimal erythema dose (MED) and of developing erythemal episodes 
during therapy (13-15).  This is usually not an issue during PUVA as the psoralen 
photosensitisation typically overwhelms any lower level photosensitisation by concomitant 
phototoxic drugs.  
 
Mechanisms 
The varied presentations of drug-induced photosensitivity and the clinical features depend on 
the mechanism by which the drug has exerted its effect through from phototoxicity to the less 
common types of drug photosensitisation, including photoallergy and drug-induced lupus.  
Overwhelmingly, drug phototoxicity is the commonest mechanism and this is a non-
immunological process, which could theoretically occur in anyone given exposure to enough 
drug and light of the relevant wavelengths and drug and light dose-dependency may be seen.  
Thus, it can potentially occur on first exposure to the drug or chemical and, on stopping the 
drug, photosensitivity should resolve.  In our experience of drug-induced photosensitivity in the 
Scottish Photobiology Service, approximately 90% of cases are thought to be due to a 
phototoxic mechanism.  There are clear differences in the modes of presentation of 
phototoxicity and photoallergy and the clinical features may be a useful guide to the underlying 
process (Table 1). 
 
Whilst photosensitivity has been reported as an adverse reaction to many drugs, there are 
common culprits, with some of the key drugs and drug classes noted (Table 2).  However, 
interestingly, with phototoxic drugs such as quinine or thiazides, idiosyncrasy is seen, with 
some patients being susceptible to only very low exposure doses of drug and/or light and 
others being either unaffected or with only sub-clinical levels of photosensitisation.  This 
idiosyncrasy may well be explained on genetic factors, such as polymorphisms in drug 
metabolising, transporter or antioxidant genes.  For example, in our own work we have shown 
that polymorphisms in the gene for the drug metabolising enzyme and antioxidant, glutathione-
S transferase M1, which is null in 50% of Caucasians, are associated with erythemal sensitivity 
to UVB, as assessed by MED and also in a separate study, with plasma psoralen levels and PUVA 
minimal phototoxic dose (MPD) and thus, at least in part, contribute to individual erythemal 
sensitivity to UVB and PUVA (16, 17).  We have also seen an association between 
polymorphisms in the melanocortin-1 receptor (MC1R) and PUVA erythemal sensitivity, as 
assessed by MPD (18).   
 
Certainly, we do not invariably see drug-induced phototoxicity at high drug doses.  However, 
given the phototoxic nature of the reaction drug dose-dependency may be observed, such as is 
seen with doxycycline whereby clinically manifest photosensitivity is more frequent at higher 
doses (19).  Indeed, doxycycline phototoxicity is reported in 3% of users at a dose of 100mg 
daily, increasing to 20% at 150mg daily and 42% at 200mg daily (19).  The characteristics of this 
photosensitivity have recently been comprehensively reviewed (20-22). 
 
Interestingly, topical phototoxicity is also seen with agents applied directly to the skin such as 
plants, dyes, coal tar, fragrances and in particular sunscreens and topical NSAIDs, the latter 
being more widely used in continental Europe than in the UK.  
 
Photoallergy to drug or chemical is much less common and indeed photoallergy to systemically 
delivered drugs is not well documented (23).  The induction of functional photomodified 
Langerhans cells after exposure to fleroxacin and UVA irradiation indicates the potential for 
fluoroquinolone-induced photoallergy after systemic delivery in mice (23).  Initial sensitisation 
is required and the mechanism appears to be of a type IV delayed T-cell mediated 
hypersensitivity reaction.  It is likely that this is initiated by covalent binding of the 
chromophore to skin protein and subsequent induction of the delayed T cell mediated 
hypersensitivity reaction.  The ability of tetrachlorosalicylanilide to form photoadducts and 
chemical modification of human serum albumin supports this mechanism of induction of 
photoallergy to topically applied photoallergens (24).  Thus, a photoallergic reaction should not 
occur on first exposure to allergen but may subsequently be triggered by only minute amounts 
of allergen and light exposure (Table 1).  Topical photoallergy to sunscreens and NSAIDs is well 
characterised, with photopatch testing being the investigation of choice for suspected 
photocontact allergy (Figure 2).  
 
Other less common mechanisms of drug-induced photosensitivity may be through the route of 
drug-induced lupus, such as with calcium antagonists, thiazides, angiotensin converting enzyme 
inhibitors (ACEI), beta blockers, terbinafine, NSAIDs, proton pump inhibitors, TNF alpha 
antagonists and cytotoxics (25-28).  Other presentations are as erythema multiforme, a 
lichenoid reaction and pellagra (29, 30).  Indeed, the same drug or drug class may induce 
diverse types of photosensitivity reaction in different subjects, such as photodistributed 
papulovesicular reactions, exaggerated erythema and lichenoid change seen in cases of 
fenofibrate photosensitivity (31). 
 
Pathogenesis 
The presumed mechanism for drug-induced phototoxicity is that drug or drug metabolite 
present within the skin, when activated by light of the relevant wavelength, acts as a 
chromophore, transferring into its excited state, producing either photoproducts or 
photometabolites, which exert a direct substrate effect or generating oxidative damage and 
free radicals which, in turn, initiate end organ effects, including photohaemolysis and 
photosensitivity (32-34).  Indeed, end organ effects may typically be of skin phototoxicity, but 
may also include photoallergy, photogenotoxicity and photomutagenesis, such as with the 
fluoroquinolones (35). 
Oxidative stress may be generated via oxygen-dependent Type I and Type II photosensitisation 
and energy transfer mechanisms (35, 36), inducing downstream effects.  These include lipid 
peroxidation, prostaglandin E2 production (37) via protein kinase C and tyrosine kinase 
activation leading to inflammation (37) and photodegradation of nucleic acid bases, as has been 
shown for ciprofloxacin (33).  Indeed, fluoroquinolone-induced DNA damage may occur via 
oxygen-dependent and -independent mechanisms involving DNA oxidation, thymine dimer 
formation and DNA base modification via alkylation (38) and photocleavage of DNA (39, 40).  
Furthermore, photoactivated naproxen has been shown in vitro to cause cell membrane and 
protein damage, lipid peroxidation and inhibition of DNA replication (34).  The role of oxidative 
stress is emphasised by the inhibitory effect of antioxidants on drug-induced phototoxicity in 
vitro (41).  The chemical structure of the molecule will influence the photochemical effects and 
photosensitising potential, and the fluoroquinolones are a prime example of this.  Within the 
fluoroquinolone class, some compounds are not significantly phototoxic, such as moxifloxacin, 
whereas others are severely phototoxic. 
  
The obvious effects of drug photosensitisation are manifest as skin phototoxicity. In addition, 
risk of ocular toxicity, particularly with drugs that photosensitise into the longer UVA and visible 
parts of the spectrum where retinal damage is theoretically feasible, needs to be considered.  
Any potential systemic toxicity is unknown but this is an area for further investigation.  
Furthermore, reduced efficacy of drug may also be a consideration in that photodegradation on 
exposure to light may result in reduced therapeutic effectiveness, constituting an adverse 
effect.  Thus, these acute effects are to be considered in the short-term, but longer-term, 
pigmentation, ocular damage and potential photoageing and photocarcinogenesis need to be 
kept in mind and this will be discussed further. 
 
Clinical presentation 
There are many potential drug culprits, with the commoner drugs and drug classes as indicated 
(Table 2).  As most photoactive drugs maximally photosensitise to UVA wavelengths this does 
mean that clinical features of photosensitivity may be triggered not only by direct sunlight, but 
also by window glass-transmitted light, on cloudy days and by sunbeds.  There are also many 
ways that phototoxicity can clinically manifest itself (Table 3).  One of the most common 
presentations is of an immediate prickling, burning sensation on sunlight exposure affecting 
photo-exposed sites (such as the face, sides and back of neck, front of chest, back of hands and 
extensor surfaces of the arms) (Figure 3) in an individual taking a phototoxic drug, and the 
appearance of an immediate or early onset erythema, perhaps as a solar urticaria-like 
presentation and sometimes a more persistent delayed erythema with pigmentation.  Examples 
of drugs that can present in this way include amiodarone, non-steroidal anti-inflammatory 
drugs (NSAIDs) such as benoxaprofen, which is no longer available, and chlorpromazine.   
 
An exaggerated more delayed sunburn-like reaction on photo-exposed sites, with sparing of 
photo-protected sites, such as under the chin, upper eyelids, behind the ears (Wilkinson’s 
triangle) and under clothing, can also be a manifestation of drug phototoxicity.  For example, 
this can occur with quinine, thiazides or tetracyclines, notably doxycycline and demeclocycline.  
Some drugs produce an interesting phototoxicity in that erythema may be delayed, and the 
classical example of this is of the psoralens as seen both in PUVA and also with 
phytophotodermatitis (Figure 4), where erythema is not evident until at least 24 hours after 
exposure and becomes more obviously manifest by 48 hours, peaking at around 72-96 hours, 
and subsequently tailing off and being replaced by prominent pigmentation.   
 
The presence of a dermatitis (eczematous reaction) on photo-exposed sites in association with 
photoactive drug ingestion may raise the possibility of a photoallergic mechanism, although 
chronic repeated episodes of phototoxicity may indeed manifest as a dermatitis.  In this setting 
other possible photosensitivity conditions, in particular chronic actinic dermatitis, should be 
considered in the differential diagnosis and ruled in or out based on investigation and follow 
up. It is unclear whether ingestion of a photoactive drug, such as a thiazide, may lower the 
threshold for triggering of other photosensitivity diseases, such as polymorphic light eruption.  
There is no firm evidence in support or dispute of this, although based on our own experience 
in the Scottish Photobiology Service we certainly consider this to be a possibility.  
 
In addition, some drugs may photosensitise not by the parent compound but through drug 
metabolite effect.  One example of this type of presentation is that of photo-exposed site 
telangiectasiae caused by calcium antagonists(42, 43).  This is of particular prevalence in organ 
transplant recipients (44) and is thought to be due to photoactive metabolites (45).  As such, it 
may take longer than a year after discontinuation of drug for the photodistributed 
telangiectasiae to resolve.  Hyperpigmentation may also be induced (46, 47).   
 
Phototoxicity may manifest itself as a lichenoid reaction or as a pseudoporphyria due to basal 
membrane damage due to the phototoxic insult.  In pseudoporphyria, the clinical presentation 
of photo-exposed site fragility, blistering and milia can be indistinguishable from porphyria 
cutanea tarda, which is the main differential diagnosis, although the porphyrin profile will be 
essentially normal.  Examples of drugs that can cause pseudoporphyria include the propionic 
acid NSAIDs such as naproxen, tetracyclines, notably doxycycline, retinoids, amiodarone, 
sulphonylureas, furosemide and nalidixic acid (29, 48, 49).  Furthermore, some photoactive 
drugs may even cause skin appendage damage such as photo-onycholysis, reported with many 
photoactive drugs, including psoralens, fluoroquinolones and doxycycline (22, 50-53).  The 
mechanism of this is again thought to be due to phototoxic insult. 
 
Persistent light reaction 
The term persistent light reaction (PLR) was coined to describe a state of continued 
photosensitivity, manifest as a dermatitis after an initial episode of photocontact allergy, 
confirmed by positive photopatch tests, with subsequent ongoing photosensitivity even after 
withdrawal of the culprit topical photoallergen, typically halogenated salicylanilide or musk 
ambrette (54-60).  The term was later encompassed within the spectrum of chronic actinic 
dermatitis and indeed, there is no convincing evidence in support of the PLR, with most cases 
retrospectively now being considered to fall within the spectrum of chronic actinic dermatitis 
(61, 62). 
 
Drug culprits 
Whilst large numbers of drugs and chemicals have been implicated as possible photosensitisers, 
in practice these should be grouped into the more commonly encountered drug categories, of 
which common culprits are noted (Table 2).  Although there are many drugs reported to cause 
drug-induced phototoxicity, some of the more common groups or classes of drugs include the 
psoralens, diuretics, certain antibiotics, antifungals, antipsychotics, calcium antagonists, 
amiodarone, retinoids, quinine, NSAIDs and the endogenous porphyrins, which of course can 
also be used exogenously in photodynamic therapy (PDT) (29, 63-68), (48, 69-72).  In Dundee 
the most commonly encountered phototoxins are thiazide diuretics, with amiodarone, NSAIDs, 
quinine, doxycycline and calcium antagonists also being culprits. 
 
The thiazide diuretics appear to exert their effects often by idiosyncratic processes, and several 
mechanisms may be involved.  Most commonly, thiazides will photosensitise via phototoxicity 
but thiazide-induced lupus, pseudoporphyria and a lichenoid reaction can also uncommonly 
occur.  Due to bioavailability of drug, if drug is stopped, then photosensitivity typically resolves 
but may persist for 3-6 months and phototesting may be abnormal for this period (63, 73).  A 
change to a non-photosensitising loop diuretic such as bumetanide may be advisable, as 
furosemide can itself induce phototoxic blistering (74).  Other examples of potent phototoxins 
include amiodarone and chlorpromazine, both of which elicit photosensitivity through a UVA-
dependent mechanism, as do thiazides, although the thiazides also photosensitise into the UVB 
part of the spectrum (63, 64, 75-77).  On cessation of chlorpromazine there is rapid resolution 
of photosensitivity, whereas in contrast, with amiodarone, this can take 9-12 months for 
photosensitivity to resolve once treatment is discontinued.  With both chlorpromazine and 
amiodarone it is common to encounter hyperpigmentation at sites of previous phototoxicity.  
Furthermore, with amiodarone, an iodoacneiform eruption may also occur on photodistributed 
sites.   
 
Quinine is an idiosyncratic photosensitiser and both quinine and NSAID ingestion need to be 
probed for in the history as many patients will not volunteer this information regarding these 
drugs as prescribed or over-the-counter medications (78).  The mechanism for quinine-induced 
photosensitivity is considered to be phototoxic, although a lichenoid pattern may also occur, 
and the presentation may be clinically very similar to that of thiazide or doxycycline-induced 
photosensitivity.  Profound dyspigmentation may be a feature and vitiliginous changes 
consistent with leukomelanoderma, due to temporary melanocyte dysfunction can be induced 
by hydrochlorothiazide (79).  The action spectrum for induction of quinine photosensitivity 
involves both the UVA and UVB parts of the spectrum (78) and, on cessation of drug, 
photosensitivity can persist for 6 months or longer.  The mechanism of quinine phototoxicity 
has been investigated and there does appear to be a fluorescent photoproduct or metabolite 
and possibly an intracellular target as there is no evidence of photohaemolysis (78).  Whilst the 
calcium antagonists may uncommonly induce phototoxicity, as mentioned the more typical 
presentation is of photoinduced telangiectasiae, sometimes with hyperpigmentation (42, 43, 
45).   
 
The antibacterial fluoroquinolones contain a fluorine atom at position C-6 and in some of the 
fluoroquinolones there is also a halogen present at C-8.  Photosensitivity and indeed 
photocarcinogenesis are well documented in pre-clinical models, with lomefloxacin, fleroxacin, 
ofloxacin and ciprofloxacin being reported as phototoxins (35, 80-82).  Photosensitivity may be 
attributed to photodehalogenation, in addition to reactive oxygen species generation and 
energy transfer (35).  Indeed 6, 8 photodehalogenation appears to be associated with increased 
phototoxicity, such as with lomefloxacin, fleroxacin and sparfoxacin, whereas methoxy 
substitution as with moxifloxacin, significantly reduces photosensitising potential (35).  Indeed, 
lomefloxacin is considered one of the more phototoxic fluoroquinolones in humans, although 
several are implicated as photosensitising in the clinical setting, with occurrence rates reported 
at up to 3%, although possibly higher with prolonged use (35, 83-90).  The action spectrum for 
induction of fluoroquinolone phototoxicity is the UVA region extending into the longer UVA and 
visible parts of the spectrum (Figure 1).  Interestingly, on cessation of drug, photosensitivity 
resolves generally within 48 hours.  There is wide variation in degree of photosensitisation 
within the fluoroquinolone drug class ranging from being no more phototoxic than placebo 
control through to having a photosensitising index of >90 (63-66, 72).  Interestingly, studies 
have also shown that certain fluoroquinolones are also photogenotoxic, photomutagenic and, 
in animals, photocarcinogenic with a single dose of drug and light exposure.  This provides an 
insight into the association between drug-induced phototoxicity and photocarcinogenesis (35, 
91).  There is reasonable correlation between in vitro and in vivo testing and the pre-clinical 
studies are usually fairly informative for potential risk of photosensitivity in humans.  
Fluoroquinolones can additionally cause hyperpigmentation, which seems to be due to drug-
melanin interaction, with impact on melanogenesis and deposition of melanin, which can 
persist for over a year. (63, 92-94). 
 
Topical Photosensitisation 
This can also be through the mechanisms of phototoxicity or photoallergy, and the drug and 
chemical classes which are associated with topical photosensitisation include diverse groups 
within the plants, dyes, tars, pitches and topical drugs such as phenothiazines, NSAIDs, 
absorbent sunscreen chemicals and porphyrins, as used in topical PDT.  Whilst plants or herbal 
substances are rarely documented to cause photosensitivity by systemic route of delivery (95), 
topical photosensitivity and phototoxicity are well recorded.  Topical photoallergy is less 
common and shall be discussed further.   
Topical phototoxicity : This is exemplified by psoralen photosensitisation in 
phytophotodermatitis, whereby fungicidal 5-methoxypsoralen and 8-methoxypsoralen in plants 
and fruits and vegetables such as limes, hogweed, cow parsley and celery come into contact 
with skin and, in the presence of UVA, initiate psoralen-induced phototoxicity, which is usually 
manifest clinically as linear erythema and blistering commencing about 24-48 hours after 
exposure and peaking at 72-96 hours (Figure 4).  Given that there is no defined investigation of 
choice, this is an important clinical picture to be aware of as it has on occasions been confused 
with non-accidental injury in children (96). 
Topical photoallergy: Photoallergic dermatitis to topical delivery of photoallergen was initially 
documented in the wake of the epidemic of “soap photoallergy”, attributed to photocontact 
allergy to halogenated salicylanilides (59, 60).  These antibacterial photoallergens were later 
superseded by other more commonly encountered substances, namely perfumes, absorbent 
sunscreens agents and topically applied NSAIDs, such as the very potent phototoxin and 
photoallergen ketoprofen (97-105).  Although photocontact allergic dermatitis is uncommon 
(106), it must be considered and not missed.  Guidelines regarding consensus methodology for 
photopatch testing as the key investigation in the diagnosis and management of patients with 
suspected photollergic dermatitis are well established (104, 107-110).  The source of 
photoallergen may be elusive and thus the potential for this diagnosis must be considered and 
photopatch testing undertaken in that setting.  As examples, a topical derivative of 
chlorpromazine, chlorproethazine, used as a non-prescription muscle relaxant, proved to be a 
potent phototoxin and photoallergen (111).  Additionally, occupational exposure to carprofen 
used for veterinary purposes was a diagnostic challenge when an outbreak of photoallergic 
dermatitis was detected in a factory setting, emphasising the importance of photopatch testing 
as a diagnostic tool (Figure 2).  It also emphasises the need to consider agents not necessarily 
included in standard batteries for photopatch testing as carprofen in fact turned out to be a 
potent photoallergen (112). 
 
With potential for topical photoallergy and current exposure patterns and tonnage use, the 
main culprits for topical photoallergy are currently the absorbent sunscreens and NSAIDs. 
Sunscreens have their own history with respect to usage and photoallergy.  Initially PABA and 
its esters were most frequently implicated, replaced by the benzophenones and to a lesser 
extent cinnamates and subsequently the dibenzoylmethanes (104, 107-110).  In recent years, 
more recently introduced sunscreen chemicals, such as octocrylene, have been reported to 
cause topical photoallergy.  This compound is a relatively frequent cause of topical 
photoallergic dermatitis in children, in addition to benzophenones and cinnamates (110, 113, 
114).  Awareness of cross-reactivity is important and often for example cross-reactions are seen 
between ketoprofen, octocrylene, benzophenones and fenofibrate (31, 102, 105, 110, 113). 
 
Therapeutic use of drug photosensitisation 
The use of the Ammi majus plant and sunlight for the treatment of vitiligo in Ancient Egyptian 
times was the first documentation of the therapeutic use of drug and chemical-induced 
phototoxicity and was the origins of PUVA therapy.  Psoralens are widely used in dermatology 
departments in both topical and oral photochemotherapy (PUVA) and this controlled 
phototoxicity can be a profoundly effective treatment for many inflammatory and chronic skin 
conditions such as psoriasis and eczema (1).  However, high cumulative PUVA exposure does 
significantly increase the risk of squamous cell carcinoma of the skin (115-121).  This again 
highlights the association between phototoxic drugs and risk of photocarcinogenesis (91).   
 
In the context of the use of controlled phototoxicity for therapeutic purposes, the initial 
observation in vitro of drug-induced photodynamic effect was reported by Oscar Raab in 1900 
when working with Von Tappeiner as a medical student undertaking studies incubating 
paramecia with acridine dyes for antimalarial purposes.  It was observed that, in the presence 
of light, there was increased cell killing of paramecia, highlighting the drug-induced phototoxic 
effect and leading to the term “photodynamic reaction” subsequently being coined (122).  
 
Photodynamic therapy is a process of delivering controlled phototoxicity in the presence of 
oxygen, generally using exogenous porphyrin-based photosensitisers.  Paradoxically this can be 
used in the treatment of superficial non-melanoma skin cancer using fluorescent topical 
porphyrin precursors, in particular 5-aminolaevulinic acid and methylaminolevulinate (Figure 5) 
and red LED light irradiation (2).  It is also of interest that during the irradiation phase of topical 
PDT a prickling painful sensation is commonly experienced, consistent with that encountered 
with other drug photosensitisers and natural sunlight (2).  Systemic PDT using systemic delivery 
of photosensitiser, such as Photofrin and fibre optic light delivery through a bronchoscope or 
endoscope, for example in the treatment of bronchial carcinoma or other accessible solid organ 
tumours, can also be undertaken.   
 
Clinical assessment 
Investigations of drug-induced photosensitivity in clinical practice should always be based on an 
initial thorough history and examination, as clinical assessment is of paramount importance.  A 
detailed drug history in terms of chronology of when drugs were started and stopped and the 
timing of dose increments is essential.  Many elderly patients receiving polypharmacy also fall 
into the category of patients for whom other photosensitivity diagnoses, such as chronic actinic 
dermatitis, should be considered in the differential.  As such, it is important that a full and 
complete evaluation is undertaken and, for any patient taking drugs with a photo-exposed site 
presentation, these should be considered as possible culprits.   
 
Investigations 
In terms of investigation of drug-induced photosensitivity, monochromator phototesting is the 
Gold Standard, and this is undertaken in tertiary specialised photodiagnostic centres (12, 123) 
(Figure 6).  This involves a filtered xenon arc source to allow light to be delivered relatively 
monochromatically across the solar spectrum, from UVB through to UVA and into the visible 
part of the spectrum.  Phototesting patients whilst taking potential photoactive drugs will 
generally show either isolated UVA sensitivity or disproportionate UVA photosensitivity 
compared with UVB sensitivity and immediate abnormal urticarial reactions may be evident, in 
addition to abnormal delayed erythema.  UVB photosensitivity may be present with some drugs 
such as the thiazides or quinine but is usually disproportionately not as prominent as UVA 
photosensitivity (12).  Thus, monochromator phototesting may be invaluable in distinguishing 
drug-induced photosensitivity from other photosensitivity diseases, in particular chronic actinic 
dermatitis (Figures 3 & 6).  In addition, involvement of the visible part of the spectrum, 
particularly the 400-430 nm region may occur (Figure 1).  The preference ideally is to phototest 
patients “on drug” and thereafter to suggest stopping a possible culprit drug and retesting at an 
interval “off drug” based on understanding of the nature of the drug.  For example, with 
fluoroquinolones retesting one week later should result in normal results, whereas with 
thiazides it may be an interval with of 3-6 months before improvement and resolution of 
photosensitivity is seen.   
Some drugs may cause photosensitivity via disruption of porphyrin metabolic pathways, and 
drugs such as vemurafenib have been implicated in this regards (124).  However, this has not 
been substantiated (125) and further mechanistic studies are warranted.  Plasma porphyrin 
scan should always be undertaken in suspected drug-induced photosensitivity as the early 
pricking burning sensations seen with drug photosensitivity may also occur in erythropoietic 
protoporphyria.  Furthermore, some drugs can photosensitise via drug-induced lupus, and thus 
ANA, ENA and histone antibodies should also be assessed.   
 
Photopatch testing is not a reliable method for investigating topical or systemic drug-induced 
phototoxicity (100, 126) and the indication for photopatch testing is to investigate suspected 
photocontact allergy (Figure 2), in particular to topical absorbent sunscreens or, in continental 
Europe in particular, topical use of NSAIDs (104, 107-110).  A European consensus is available 
for photopatch testing and this includes a battery of standardised absorbent sunscreen 
chemicals and NSAIDs agents (109, 110).  The technique involves application of duplicate series 
of photoallegens and irradiation of one set at 24-48 h, with readings, interpretation and 
relevance undertaken using standard patch testing methods (104, 107-110).  Interpretation 
may be difficult if a patient has a co-existing photosensitivity disease. However, photopatch 
testing should always be considered in a patient with a photoexposed site dermatitis, especially 
if there is a history of sunscreen or topical NSAID use or if a patient with a known 
photosensitivity disease deteriorates for no apparent reason (104, 110, 127).  This investigation 
has somewhat fallen between the interests of the photobiologists and contact dermatologists 
and further refinement of the standardised technique is under evaluation in a current European 
photopatch test study.  
 
Management 
In practice, if a photosensitising drug is identified then, if possible, administration should be 
stopped. Photoprotection with behavioural modification, clothes, hats and appropriate broad 
spectrum high SPF sunscreen, including reflectant titanium dioxide if longer UVA and visible 
wavelengths are involved, should be used whilst on drug and after discontinuation until 
photosensitivity has normalised (128).  If the drug cannot be stopped, such as for example with 
amiodarone, UVB desensitisation may be cautiously used to induce tolerance (129). 
 
Regulatory Requirements 
Historically, knowledge of potential drug photosensitivity as an adverse effect to any new drugs 
coming to market was provided by anecdotal reports and post-marketing surveillance.  In order 
for a drug to be photosensitising it must be able to absorb and initiate a photochemical 
reaction. Predictive information relating to new potentially photoactive drugs is important 
(130).  Regulatory guidance (FDA and EMA) is that photosafety investigations must be 
undertaken for drugs that absorb between 290-700 nm and are applied systemically or topically 
and reach the skin or eyes (91, 131-134).  In practice, many drugs fall into this category and 
both in vitro and ex vivo studies are indicated and subsequently controlled trials in human 
volunteers may be required for a potentially phototoxic drug.  Molecules of low molecular 
weight, containing aromatic halogen atoms, with extended conjugation of double bonds and of 
high triplet yield are more likely to be photosensitisers (11, 134).  In addition to light 
absorption, photodegradation, formation of singlet oxygen or superoxide anion in vitro should 
also trigger the need for photosafety testing (134).  The initial investigations in vitro would 
involve establishing absorption spectra and understanding the underlying mechanisms and the 
molecular structure of drug and whether metabolites and photoproducts are likely.  Mass 
spectrometry may be of use in demonstrating photodegradation, as with sparfloxacin following 
UVA irradiation(135, 136).  Drug-induced phototoxicity should be investigated in vitro and 
photoclastogenicity, photomutagenicity and photocarcinogenicity studies may be considered, 
although the International Genotoxicity Testing Working Group concluded that 
photogenotoxicity studies were not recommended as part of standard photosafety evaluation, 
based on an expert panel workshop assessment that these studies were of negligible additional 
value (130).  Subsequently, if the in vitro and animal study (137, 138) signals are positive, then 
in vivo human volunteer testing should be undertaken.  The in vivo and ex vivo studies may be 
useful as predictors but the reliability of these is not high in that often a positive signal in, for 
example, the 3T3 neutral red assay in vitro, does not necessarily indicate that a drug will be 
phototoxic when used clinically.  The 3T3 neutral red assay is accepted as the standard pre-
clinical method of in vitro testing for drug phototoxicity (139) and the photocomet assay for 
evidence of DNA damage (140).  Indeed, pre-clinical in vitro non-animal phototoxicity and 
photoallergy testing may be employed in photosafety evaluation, with endeavours to improve 
specificity and sensitivity and in certain settings may minimise the need for animal and human 
studies (141).  Photosensitivity to topical agents is often investigated in animal models of skin 
reactions and also in a murine local lymph node assay (LLNA) and may also be adapted for use 
in the investigation of the phototoxic potential of systemically delivered compounds.  This 
appears to have supportive utility in the preclinical photosafety assessment of potentially 
phototoxic drugs, based on establishing a photoirritation factor, which in turn may help to 
triage those drugs that need to go on to testing in the human setting (139). 
 
Healthy Volunteer Testing 
Times have moved on from the volunteer testing involving sending subjects who had taken 
drug on a lengthy boat trip in sunny climes (63, 142).  The definitive healthy volunteer study 
involves a combination of monochromator phototesting and polychromatic solar simulator 
phototesting at baseline and then on steady state of drug, and if the drug is photosensitising, to 
repeat the phototesting until the photosensitivity has returned to the normal range (63, 67, 84, 
93, 143).  An adequately powered randomised controlled double blind clinical trial format is 
desirable, including a positive control, such as ciprofloxacin (93), in addition to the drug under 
investigation.  This is in order to provide reassurance of the validity of the experimental set up 
and to assist with blinding of assessments.  The phototoxic index (PI) should be defined at each 
narrow waveband tested and is helpful in objectively defining the level of photosensitivity at 
each of the monochromator wavebands tested across the spectrum.  The PI is determined 
based on the baseline minimal erythema dose (MED) “off drug” as a ratio of the MED at that 
same waveband “on drug”.  There is marked variation in degrees of phototoxicity between 
drugs within the fluoroquinolone class but, in addition, between individuals and this variation, 
with ciprofloxacin for example, is not explained based on skin type, and idiosyncratic genetic 
factors are likely to be involved (63, 67, 69).  However, this robust clinical trial design in healthy 
volunteers, with positive and negative controls, may provide essential information on whether 
a drug is significantly phototoxic in humans.  If this is the case then it will also provide 
information on wavelength-dependency and the degree of sensitivity at specific wavebands. It 
may also allow information on drug-induced pigmentation secondary to phototoxicity to be 
established.  The effects of sunscreen and antihistamines may also be investigated through 
inclusion in the experimental design.  These predictive data may provide reassurance for 
regulatory purposes that a drug with positive pre-clinical phototoxicity testing is either unlikely 
to be phototoxic when used clinically or indeed requires caution.  This is important with respect 
to further drug development and/or labelling and management advice for a drug with proven 
phototoxic risk in the clinical setting (63, 67, 69, 144, 145). 
 
Other Effects of Drug-induced Photosensitivity 
We are developing some understanding of the pigmentation that is induced by some 
phototoxic drugs.  For example, with the tetracyclines this appears to be drug complex 
deposition, whereas with the fluoroquinolones, this is via melanogenesis (63, 92-94). 
What is less well understood is potential systemic toxicity from photosensitising drugs.  There is 
evidence that fluoroquinolone phototoxicity in animals can result in animal death but the role 
of systemic phototoxicity in humans is unclear.  Furthermore, some photoactive drugs, 
particularly those that sensitise in the visible part of the spectrum, may carry with them 
unknown risk to the retina and ocular damage.  This needs to be considered for any drug that 
photosensitises certainly to the longer UVA and visible wavelengths. Indeed, in animal model 
testing, histopathological analysis of the retina is advisable for drugs photosensitising to visible 
wavelengths (139). 
 
Drug-induced phototoxicity and photocarcinogenesis 
There is overwhelming evidence for the photocarcinogenic effects of psoralens 
(furocoumarins), when irradiated by UVA (PUVA) in vitro, in animal models and in humans, so 
much so that it is used as positive control for photocarcinogenesis in many pre-clinical studies 
(91, 115-121, 146).  Monoadduct formation in the 5’6’ double bond of thymidines and 
subsequent UVA-induced photoactivation causes DNA crosslinking and DNA repair is prevented 
by both these PUVA mutations and signature UVB mutations, leading to tumourigenesis (40).  It 
is also well documented that fluoroquinolones can induce photogenotoxicty (40, 147) and 
phototumourigenesis in animals after systemic delivery and UVA exposure (80-82). 
Lomefloxacin and fleroxacin induced invasive squamous cell carcinomas in an animal model 
following UVA irradiation, even after a single exposure, which is of concern.  Induction of 
cyclobutane pyrimidine dimers in double-stranded DNA by triplet-triplet energy transfer is 
thought to be at least one of the mechanisms implicated in the phototumourigenesis of 
lomefloxacin, in addition to both Type I and Type II oxidative reactions (36, 83, 148, 149). 
 
Additionally, there is a growing body of evidence for photocarcinogenic risk of several 
photosensitising drugs (150-155).  In a multicentre questionnaire-based case control study of 
1732 patients with skin cancer (SCC, Melanoma and/or BCC) and 1550 controls, associations 
between ciprofloxacin or thiazide ingestion and SCC risk were documented (150).  
 
In a separate Dutch case control study of 1318 cases and 6786 controls, the use of quinolone 
antibiotics and propionic acid derivative NSAIDs was associated with increased risk of 
melanoma, even when used only short-term (154).  Furthermore, in a large population-based 
case control study in Denmark, an association was seen between the use of thiazides or 
amiloride and risk of melanoma (151).  Thus, possibly the risk of skin cancer with 
photosensitising drug may be greater for SCC and melanoma than BCC, although there are 
reports suggestive of a possible increased risk of BCC, such as with amiodarone, ciprofloxacin or 
tetracycline (152, 156-159).  
 
In one population case control study in New Hampshire in >5000 subjects, an association with 
tetracycline use and increase risk of BCC, especially at age of <50 years was noted (153).  This 
observation of an association between photosensitising antimicrobials and early onset BCC has 
been corroborated (153).  In a further study, an increased incidence of both BCC and SCC was 
recorded in tetracycline users (152).  Indeed, associations between diuretics, especially 
thiazides, and SCC and BCC have been reported in several studies and even short-term use of 
photosensitising drugs may be significant (151-153, 155, 160).  It seems that the risk is most 
likely influenced by several factors, notably skin phototype, absorption spectrum of the drug, 
age of patient at time of taking the drug and duration of treatment and that the skin cancer 
type may also be influenced by these factors (151-153).  
 
There are well documented reports of “exaggerated sunburn” and photo-distributed rash in 
patients taking voriconazole, who are usually immunosuppressed (161-164).  Severe 
phototoxicity was reported in 8-10% of subjects (165-168) and even higher rates in patients 
with cystic fibrosis (169, 170), particularly this was photosensitivity to the UVA part of the 
spectrum (161).  The mechanism for photosensitivity is unclear and likely related to the N-oxide 
metabolite, which has peak absorption in the UVC and UVB, and UVB-photoproducts (165, 168, 
171-173).  Whilst polymorphisms in P450 CYP2C19, CYP2C9 and CYP3A4 may be implicated in 
the pharmacokinetics of voriconazole, there does not appear to be an identified association 
between phototoxicity and p450 inhibition or serum retinol levels.  There is also poor 
correlation with drug serum levels and phototoxicity (161, 170, 174, 175).   
 
However, the photosensitivity usually initially manifests as facial and photo-exposed site 
erythema, often also with cheilitis (176) and retinoid-like side effects (176).  The risk may be 
increased by immunodeficiency, either innate or iatrogenic (168-177).  A degree of suspicion of 
photosensitivity must be kept as misdiagnosis as cutaneous graft-versus-host disease may occur 
(178).  Voriconazole use has also been associated with pseudoporphyria and photoaging (166, 
179-182), discoid lupus erythematosus in one case (176) and with photocarcinogenesis, with 
both aggressive squamous cell carcinomas developing in children and adults but also with 
atypical lentigines and malignant melanomas (165, 183).  In one report, 51 squamous cell 
carcinomas occurred in eight patients, including children and patients also showed facial 
erythema and marked photoaging, lentigines, actinic keratosis, telangiectasiae and cheilitis 
(180).  The risk of skin malignancy with voriconazole has been identified (180, 184-186), 
although was not shown to be significant in one large retrospective study (177).  The 
photocarcinogenic risk does however appear to be related to duration of therapy, certainly in 
the lung transplant patient population (187), with the risk of SCC in association with chronic 
voriconazole ingestion rising to 28% at 5 year follow up post lung transplantation (186).  
 
The BRAF inhibitors such as vemurafenib have also been associated with photosensitivity (188, 
189) through a UVA-dependent early erythema and increased porphyrin levels (124), although 
this has not been consistently observed (125).  In studies of patients taking vemurafenib, more 
than 50% have been reported to be photosensitive, and also to develop naevi, 
keratoacanthoma and keratinocyte proliferations, including squamous cell carcinoma of the 
skin.  However, the mechanism of phototoxicity may be dissociated from the mechanism of 
keratinocyte proliferations as the latter may involve MEK inhibition and upregulation of the 
mitogen-activated protein kinase (MAPK) pathway (190-192).  
 
With respect to newer drugs, pirfenidone, which is an oral anti-fibrotic, anti-inflammatory drug 
used for idiopathic pulmonary fibrosis, has been shown to cause phototoxicity in more than 
12% of patients and is phototoxic both in cells and animals (193-197).  A possible photoallergic 
mechanism has been proposed, but not substantiated and use of photopatch testing in the 
setting of investigating systemic photoallergy may result in false positive or negative reactions 
and is thus difficult to reliably interpret (198).  This is a drug used chronically and other useful 
alternatives are not in abundance, and therefore management of photosensitivity is often by 
dose reduction and photoprotection in this otherwise ill group of patients.  As a photosensitiser 
and immunosuppressive agent used chronically the possibility of a photocarcinogenic risk needs 
to be considered, although any potential risk is unclear and studies are warranted.  There are 
reports of photosensitivity with other newer drug groups, such as with the HIV reverse 
transcriptase inhibitors and with the protease inhibitors and polymerase inhibitors for hepatitis 
C.  Any possible association between photocarcinogenesic risk and use of these chronic 
phototoxic drugs in immunocompromised patients must be kept in mind.   
 
Thus, undoubtedly there is an association between phototoxicity and photocarcinogenesis with 
some drugs and this is proven for psoralens.  There are also strong pointers to 
photocarcinogenesis with azathioprine.  Azathioprine induces abnormal UVA photosensitivity 
and it is likely that the interaction between DNA containing 6-thioguanine in patients taking 
azathioprine, with UVA induces mutagenic oxidative DNA damage and photocarcinogenesis 
(199-202).  This likely explains, at least in part, the marked increased risk of SCC in patients who 
have received organ transplants and who are immunosuppressed, particularly when regimens 
employing azathioprine are used (202).  However, other non-photosensitising 
immunosuppressants, such as ciclosporin also increase skin cancer risk, notably SCC, 
particularly with degree and duration of immunosuppression, emphasising the role of the 
immune system in protecting against photocarcinogenesis (202-210). 
 
The mechanisms for both phototoxicity and skin cancer development may not be one and the 
same and may be distinct.  There is of course risk of skin cancer with other groups of drugs such 
as the biologics, which are not photosensitising, and this may be through the mechanism of 
immunosuppression and immunomodulation.   
 
There are conflicting epidemiological data available regarding risks with more chronically used 
photoactive drugs such as the diuretics and antimicrobials but they could well contribute to 
increasing lifetime risk of skin cancer.  It is certainly likely that there are individual risk factors 
for photosensitivity and skin cancer with drugs that we do not fully understand, and whether 
P450s or other drug metabolising enzymes, transporters or antioxidants can be implicated in 
some instances should be considered.  Other possible culprits are melanocortin 1 receptor 
(MC1R) polymorphisms, which have been shown to subtly influence PUVA erythemal 
sensitivity, as has the glutathione S transferase, GST M1 (16-18, 211).  Patients who are null for 
the GST M1 gene have higher serum 8-MOP concentrations after standard oral doses of 8-MOP 
and lower PUVA MPDs, reflecting increased photosensitivity (17). 
 
Conclusions 
Thus, in summary, drug photosensitivity is a relatively common occurrence and a range of 
mechanisms may be involved and several investigations are available.  Regulatory requirements 
are increasing and should be adhered to for any new drugs coming to market.  Controlled 
phototoxicity is widely used therapeutically as with PUVA and PDT, for example.  There remains 
uncertainty about the risks of chronic ingestion of photosensitising drugs and systemic, ocular 
or chronic photocarcinogenic risks and we need increased understanding of the 
pharmacogenetics involving some of the idiosyncratic drug photosensitising reactions.  A level 
of suspicion and vigilance, with appropriate investigations to establish a definitive diagnosis is 
key in the clinical setting. 
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